Introduction
============

Diabetes is the world's fastest growing disease and a major threat to public health worldwide ([@B56]). Since it is a chronic disease, first and secondary prevention is key in reducing its burden on individuals and society. A prerequisite for efficient primary prevention is knowledge about factors influencing disease onset. Diabetes is a more heterogeneous disease than the crude subdivision into type 1 and type 2 diabetes implies ([@B89]; [@B43]; [@B2]); with a finer classification of diabetes based on differences in pathophysiology, opportunities arise for more accurate assessment of factors influencing disease onset and prognosis. This may allow us to identify etiological factors potentially obscured in analysis of heterogeneous patient groups with different pathogenesis and help us identify modifiable factors which may eventually lead to improved primary prevention. LADA -- latent autoimmune diabetes in adults -- is a common but understudied form of diabetes with features of both type 1 and type 2 diabetes. The aim of this review is to summarize findings regarding the role of environmental and genetic factors in the etiology of LADA, discuss potential etiological and pathophysiological overlap between LADA and type 2 diabetes, point at similarities between LADA and type 1 diabetes and the preventive potential of LADA.

Lada
====

In 1977, Irvine et al. showed that 11% of individuals initially diagnosed with type 2 diabetes have antibodies against the insulin producing beta-cells, which is a characteristic of type 1 diabetes and indicative of an autoimmune pathogenesis ([@B37]). The term LADA was introduced in 1993 by Tuomi et al. to describe this subgroup of patients that seems to share phenotypical features with type 2 diabetes and immunological features with type 1 diabetes ([@B88]). LADA has been estimated to account for 3--12% ([@B91]; [@B87]; [@B85]; [@B100]; [@B10]; [@B51]; [@B28]; [@B67]; [@B99]; [@B49]) of all diabetes in adults, being more frequent in Europe ([@B91]; [@B87]; [@B10]; [@B51]; [@B28]; [@B67]) than in other parts of the world including Asia ([@B85]; [@B99]; [@B49]) and North America ([@B100]). The majority of LADA studies conducted to date comes from European countries but an increasing number of studies are being conducted also outside Europe ([@B54]).

There is no uniform agreement on the definition of LADA but diagnosis is usually based on three criteria ([@B24]; [@B55]); (1) adult age at onset, (2) islet autoantibodies as a marker of autoimmune activity, (3) insulin independence. However, the exact application of these criteria varies; Onset should be in adulthood but the actual age limit varies, although 30 or 35 years is most commonly used. The slow onset that distinguishes LADA from type 1 diabetes with adult onset is typically defined as absence of insulin treatment during the first 6 or 12 months following diagnosis, but this criterion has been questioned since it is subjective and depends on the judgment of the treating physician ([@B8]). One alternative is to use fasting C-peptide levels as an indicator of remaining insulin secretion and a "latent" onset ([@B85]; [@B70]). The least controversial criterion is the assessment of autoantibodies as a marker of the autoimmune activity that separates LADA from type 2 diabetes. Glutamic acid decarboxylase antibodies (GADA) are most frequently used due to the fact that this antibody is far more common in patients with adult onset autoimmune diabetes than other autoantibodies often found in children with type 1 diabetes ([@B87]; [@B81]; [@B28]).

Pathogenesis
============

Type 1 and Type 2 Diabetes
--------------------------

The main pathophysiological features of type 2 diabetes are insulin resistance in skeletal muscle, liver and adipose tissue, together with impaired insulin secretion ([@B21]). Insulin resistance reduces peripheral glucose uptake and stimulates hepatic glucose output which leads to elevated blood glucose levels. The ensuing hyperglycemia increases the demand on the beta-cells for a compensatory rise in insulin secretion. This may consequently exhaust the beta-cells and lead to a progressive loss of beta-cell function, resulting in insulin deficiency and subsequent diabetes ([@B21]). Type 1 diabetes on the other hand seems to result from a distinct pathophysiological process; its main feature is insulin deficiency which is caused by autoreactive T-cells of the immune system that destroy the pancreatic beta-cells. The autoimmune reaction leads to a progressive loss of functional beta-cell mass and declining insulin production ([@B9]).

LADA
----

Similar to type 1 diabetes, LADA patients display autoantibodies which is indicative of an autoimmune pathogenesis. However, the autoimmune process seems to be milder and the progression of beta-cell failure slower; this is evidenced by the fact that LADA patients consistently display higher levels of C-peptide as indicator of insulin secretion ([@B13]; [@B35]; [@B29]) and furthermore, they are not insulin-requiring for some time following diagnosis. Compared to patients with type 2 diabetes, those with LADA have less insulin secretion ([@B91]; [@B13]; [@B29]; [@B31]) and progress to insulin dependence faster ([@B91]; [@B98]). As an example, data from the United Kingdom Prospective Diabetes Study (UKPDS) showed that among individuals initially diagnosed with type 2 diabetes, 84% of those who were GADA positive at diagnosis progressed to insulin dependence within 6 years compared to 14% of antibody negative individuals ([@B91]). Similar to what is seen in type 1 diabetes ([@B36]), autoimmunity seems to be the first pathological symptom in LADA; data from the prospective HUNT Study show that 64% of LADA patients where GADA positive several years prior to diagnosis ([@B81]) and similar findings were reported by Lundgren et al. in the Finnish Botnia Study ([@B47]).

Whereas type 1 diabetes typically is characterized by a clustering of different islet autoantibodies ([@B73]), LADA patients tend to be positive primarily for GADA ([@B87]; [@B81]; [@B28]); In Action LADA, a European multicenter study, 90% of the antibody positive patients were positive for GADA, whereas only 10% could be detected merely through antibodies to insulinoma-associated antigen-2 (IA-2A) or zinc transporter 8 (ZnT8A) ([@B28]). Moreover, multiple antibodies were found in 24% of antibody positive patients in Action LADA ([@B28]) and in 10% of LADA patients in the Norwegian HUNT Study ([@B81]). This indicates that at least for research purposes, it is enough to measure GADA in order to separate LADA from type 2 diabetes. The level of GADA is inversely related to C-peptide levels as a marker of insulin secretion ([@B65]) and GADA may therefore serve as an indicator not only of the presence of autoimmune activity but also to some extent, of the magnitude of such activity.

The fact that LADA patients have more insulin production than patients with type 1 diabetes at time of diagnosis indicates that other mechanisms besides autoimmune destruction of the beta-cells may play a role in the pathogenesis. In line with this, it has been shown that LADA patients display insulin resistance ([@B13]; [@B6]; [@B18]; [@B38]; [@B31]), although not as pronounced as in type 2 diabetes ([@B100]; [@B47]; [@B31]), which has been attributed to differences in BMI ([@B18]; [@B38]). The relative contribution of insulin resistance to the development of LADA may depend on the degree of underlying autoimmunity; both Swedish and Norwegian data show that LADA patients with less autoimmune activity as indicated by low GADA levels, tend to be more insulin resistant than those with high GADA levels ([@B31]).

Etiology
========

Genetic Factors
---------------

In type 1 diabetes, the strongest genetic influence is conferred by genes in the HLA complex which are responsible for approximately half of the genetic susceptibility ([@B58]). In contrast, the genetic influence on type 2 diabetes risk seems to be spread all across the genome and attributed to a large number of common, genetic variants -- each contributing a small amount to heritability of the disease ([@B25]). The strongest effect is conferred by variants in the transcription factor 7-like 2 (*TCF7L2*) gene, which is associated with a 30% risk increase. The majority of known type 2 diabetes-related genetic risk variants are associated with insulin secretion rather than insulin resistance ([@B25]). Similar to type 1 diabetes, LADA is closely linked to genes in the HLA complex, and furthermore, the highest risk is seen in carriers of the HLA haplotypes HLA-DRB1^∗^04-DQB1^∗^03:02 and HLADRB1^∗^ 03:01-DQB1^∗^02:01, which also confer the highest risk of type 1 diabetes ([@B22]; [@B4]; [@B64]; [@B53]). The HLA genes encode the major histocompatibility complex (MHC) that regulates the immune system, consequently these findings thus point to a strong involvement of the immune system in the pathogenesis of LADA ([@B3]). In addition, LADA is linked with type 1 diabetes associated variants outside of the HLA region including *PTPN22*, *INS*, and *SH2B3* ([@B53]). A genetic overlap with type 2 diabetes has also been reported; the most consistent finding is an association with type 2-associated variants of *TCF7L2* ([@B17]; [@B5]). This evidence comes primarily from candidate gene studies of which the largest was based on 978 LADA cases of European descent ([@B53]) however, recently the first GWAS study on LADA was published including pooled data from 2634 patients ([@B19]). This study confirms that the genetic basis of LADA primarily resembles that of type 1 diabetes, but also includes genetic variants associated with type 2 diabetes. Importantly, studies conducted to date consistently show that the excess risk of LADA conferred by HLA genotypes is far stronger than the risk observed for type 2-associated genetic variants ([@B3]). In support hereof, a recent study of family history of diabetes indicated that the risk of LADA is increased six-fold in individuals with family history of type 1 diabetes compared to 2-fold in those with family history of type 2 diabetes ([@B32]).

Lifestyle
---------

### Type 1 and Type 2 Diabetes

Strong support for a role of environmental factors in the etiology of autoimmune diabetes is provided by the world wide rise in incidence of type 1 diabetes in children ([@B23]; [@B52]), which proposedly reflects an increasingly diabetogenic environment rather than changes in the genetic makeup of the population. Still, the environmental triggers of autoimmunity and type 1 diabetes has proved difficult to map. Associations with a number of lifestyle factors have been reported, including exposure to enterovirus, several dietary factors, weight gain and psychological stress ([@B74]). Nevertheless, attempts to replicate findings across studies have often failed and intervention studies have been largely unsuccessful in preventing type 1 diabetes in children ([@B79]).

More is known about the etiology of type 2 diabetes; the risk is closely linked to a number of unhealthy lifestyle factors and among those, excess weight is the strongest risk factor; obesity is associated with a seven-fold increased risk according to a meta-analysis based on 18 prospective cohort studies ([@B1]). Low birth weight, proposedly reflecting fetal malnutrition, is also associated with an increased risk of type 2 diabetes ([@B95]). In contrast, physical activity is associated with a reduced risk ([@B80]), whereas sedentary time ([@B7]) and hours of TV viewing ([@B62]) is positively associated with incidence of type 2 diabetes. Smokers have excess risk that increases in a dose-response manner by number of cigarettes ([@B61]). Several dietary factors have also been linked to type 2 diabetes even after adjustment for BMI; Food groups associated with a reduced risk include whole grain ([@B77]), fruit and vegetables ([@B77]), alcohol (moderate vs. no intake) ([@B44]) and coffee ([@B77]), while an increased risk is associated with consumption of sugar-sweetened beverages ([@B77]), and red and processed meat ([@B77]). The preventive potential of type 2 diabetes seems to be substantial; a recent study based on the China Kadoorie Biobank including \>400 000 participants estimated that the combination of healthy BMI, waist-hip ratio (WHR) and diet together with non-smoking could prevent 3/4 of all cases of type 2 diabetes ([@B48]). Similar findings have been reported in Europe ([@B42]) and in different ethnic groups in the United States ([@B83]). The biological mechanism linking the majority of these lifestyle factors to type 2 diabetes primarily involves promotion of insulin resistance or beneficial effects on insulin sensitivity ([@B63]). Since LADA, in addition to autoimmunity, seems to be characterized by insulin resistance it may be hypothesized that environmental or lifestyle factors known to promote insulin resistance may also increase the risk of LADA.

### LADA

There are few studies on the influence of lifestyle factors on the risk of LADA ([@B14]) and the reason for this is most likely lack of data. Prerequisites for such studies are; (a) information on incident cases of LADA which requires antibody testing in order to separate LADA from type 2 diabetes, (b) a suitable non-diabetic population for comparison, (c) detailed information on lifestyle factors from the time before diagnosis, and (d) enough patients for viable analyses. Characteristics of some of the largest individual LADA studies to date are presented in [Table 1](#T1){ref-type="table"}. From the table it is evident that few studies fulfill these criteria and consequently, the risk of LADA in relation to lifestyle factors has so far only been investigated with data from the Norwegian HUNT (Nord-TrØndelag Health) Study ([@B41]) which is the world's only prospective cohort study of LADA ([@B31]), and the Swedish ESTRID (Epidemiological Study of Risk Factors for LADA and Type 2 diabetes) Study ([@B70]) which is a case-control study with incident cases recruited from the ANDIS (All new diabetics in Scania) biobank ([@B2]) and incidence density sampled controls ([@B92]). Both studies are population-based and according to the most recent publication based on these data bases, the number of LADA patients is 147 in the HUNT Study and 425 in the ESTRID Study ([@B31]). With data from these two studies, it is possible to calculate separate risk estimates for LADA and type 2 diabetes using the same reference population, exposure and confounding assessment. Unfortunately, patients with type 1 diabetes are not included in the ESTRID-study, and the HUNT-study has too few incident cases of adult onset type 1 diabetes for viable analyses. For that reason, comparisons between LADA and type 1 diabetes has to be based on findings in children from other cohorts. There are additional, larger LADA studies based on pooled data (e.g., 40 and 46) that are not described in [Table 1](#T1){ref-type="table"}, however, neither of these studies report information on lifestyle factors. ESTRID and HUNT studies have been approved by ethical boards for medical research in Sweden and Norway and all participants gave informed consent.

###### 

Description of some of the largest individual LADA studies to date.

  Reference   Study              Setting                 Time period   Study design                                            Study participants                                                              No. cases   LADA definition                                                                   Time since diagnosis   Genetic information   Lifestyle information
  ----------- ------------------ ----------------------- ------------- ------------------------------------------------------- ------------------------------------------------------------------------------- ----------- --------------------------------------------------------------------------------- ---------------------- --------------------- -----------------------
  [@B4]       Botnia             Finland                 1990          Cross-sectional (with prospective part)                 Patients recruited through primary care and their family members                213         ≥35 years, GADA positive, no insulin ≤6 months                                    Not mentioned          Yes                   None presented
  [@B10]      NIRAD              Italy                   2001--2004    Cross-sectional with prevalent cases                    Patients recruited through 83 diabetes clinics                                  193         Adult onset, GADA or IA-2A positivity, non-insulin requiring,                     6 months to 5 years    Yes                   None presented
  [@B28]      Action LADA        Europe                  2004--2007    Cross-sectional with prevalent cases                    Patients recruited through primary care or hospital settings.                   598         30--70 years, GADA/ IA-2A or ZnT8A positivity, no insulin ≤6 months               \<5 years              None presented        None presented
  [@B31]      ESTRID             Sweden                  2010          Case-control with incident cases and matched controls   Patients recruited through primary care and controls from population registry   425         ≥35 years, GADA positive, remaining insulin production indicated by C-peptide     Median 5 months        Yes                   Yes
  [@B49]      ICLDC database     United Arab Emirates    2013          Cross-sectional with prevalent cases                    Patients attending the Imperial College London Diabetes Centre                  437         \>30 years, GADA or IA-2A positivity, non-insulin requiring                       ≤10 years              None presented        None presented
  [@B51]      --                 Sardinia                2000--2005    Cross sectional                                         Patients recruited through five diabetes units                                  251         35--70 years, GADA positivity, no insulin ≤8 months                               0--5 years             Yes                   None presented
  [@B67]      HUNT               Norway                  1984--2008    Prospective cohort study with incident cases            General population in the County of Nord-TrØndelag in Norway                    140         ≥35 years, GADA positivity                                                        Incident cases         Yes                   Yes
  [@B85]      Ehime study        Japan                   1998--99      Cross-sectional study with prevalent cases              Patients recruited through hospitals                                            97          \>20 years, GADA positivity, remaining insulin secretion indicated by C-peptide   Mean \> 10 years       Yes                   None presented
  [@B91]      UKPDS              United Kingdom          1977--1991    Cross-sectional                                         Patients recruited through 23 centers                                           430         25--65 years, GADA/ autoantibodies toislet-cell cytoplasm (ICA) positivity        "newly diagnosed"      No                    None presented
  [@B97]      --                 Denmark                 1997--2013    Cross-sectional with prevalent cases                    Patients referred to the University hospital in Odense                          327         ≥18 years, GADA positivity, remaining insulin secretion indicated by C-peptide    Not mentioned          None presented        None presented
  [@B99]      LADA China Study   China                   2006--2010    Cross-sectional with newly diagnosed cases              Patients recruited through 46 hospitals                                         287         ≥30 years, GADA positive, non-insulin requiring                                   \<1 year               Yes                   None presented
  [@B100]     ADOPT              United States, Europe   2000--2002    Cross-sectional with prevalent cases                    Patients recruited through 488 center                                           174         Adult onset, GADA positivity, non-insulin requiring                               3 years                None presented        None presented
                                                                                                                                                                                                                                                                                                                                                          

#### Environmental factors in LADA associated with insulin resistance and type 2 diabetes

Findings of the studies on lifestyle and risk of LADA compared to type 2 diabetes conducted to date are summarized in [Figure 1](#F1){ref-type="fig"}. In support of a role for insulin resistance and a type 2-like etiology, these studies indicate that LADA may share several risk factors with type 2 diabetes; Excess risk of LADA is seen in relation to overweight ([@B31]), adiposity ([@B31]), low birth weight ([@B34]), and sweetened beverage intake ([@B46]), whereas the risk is reduced in those with moderate alcohol consumption ([@B66], [@B69]) and high physical activity ([@B15]; [@B30]; [Figure 1](#F1){ref-type="fig"}). The associations are generally weaker for LADA than for type 2 diabetes ([Figure 1](#F1){ref-type="fig"}), which is not surprising since insulin resistance can be expected to be less important in disease progression in the presence of autoimmunity and a more pronounced insulin deficiency. This is particularly evident for BMI; as shown in [Figure 2](#F2){ref-type="fig"}, data from the ESTRID study (data set described in [@B31]) indicate that the risk of both LADA and type 2 diabetes increases progressively with BMI but more dramatically for the latter. Furthermore, the excess risk of LADA conferred by high BMI is stronger for less autoimmune LADA (GADA \< median), even though it is also seen for more autoimmune LADA (GADA \> median) ([Figure 2](#F2){ref-type="fig"}). This is in line with findings of cross-sectional studies, including the NIRAD (Non-Insulin Requiring Autoimmune Diabetes) ([@B10]) and Action LADA ([@B28]) studies showing that LADA patients with low GADA have higher BMI and higher prevalence of the metabolic syndrome than those with high GADA levels.

![Relative risk and 95% confidence interval for LADA and type 2 diabetes in relation to lifestyle factors. Results from ESTRID and HUNT studies. Estimates for low birth weight, sweetened beverages, coffee intake and fatty fish are based on data from the ESTRID Study (extracted from [@B45], [@B46]; [@B34]; [@B68]); estimates for BMI, smoking, physical activity and alcohol intake are based on pooled data from ESTRID and HUNT studies (extracted from [@B66],[@B67], [@B68], [@B70]; [@B30],[@B31]); estimates for WHR is based on the HUNT Study ([@B31]).](fphys-10-00320-g001){#F1}

![Relative risk of LADA and type 2 diabetes **(A)**, and LADA with high and low GADA levels **(B)** in relation to Body mass index.](fphys-10-00320-g002){#F2}

With regard to underlying mechanisms, results based on the ESTRID Study indicate that BMI ([@B31]) and smoking ([@B70]) are positively associated with insulin resistance calculated by homeostasis model assessment (HOMA-IR) ([@B86]) in LADA, with a similar non-significant tendency for sweetened beverage intake ([@B46]), whereas there is an inverse association between alcohol consumption ([@B69]), physical activity ([@B30]) and insulin resistance ([Table 2](#T2){ref-type="table"}). In contrast, there is no indication that the mechanism linking any of these factors to LADA includes a triggering or exacerbating effect on autoimmunity ([Table 2](#T2){ref-type="table"}). [Figure 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"} displays the association between BMI and HOMA_IR and GADA in LADA and type 2 diabetes based on the ESTRID-study (data set described in [@B31]). These data indicate that BMI is positively associated with HOMA_IR both in patients with LADA and type 2 diabetes ([Figure 3](#F3){ref-type="fig"}) which fits with previous observations ([@B18]). GADA, on the other hand, was inversely associated with BMI among LADA patients ([Figure 4](#F4){ref-type="fig"}).

###### 

Lifestyle factors and associations with risk of LADA, insulin resistance and GADA, results based on HUNT and ESTRID studies.

                                                          Norwegian HUNT Study   Swedish ESTRID Study         
  ------------------ ------------------------------------ ---------------------- ---------------------- ----- ---
  *Increased risk*   Overweight/obesity ([@B31])          ↑                      ↑                      ↑     ↓
                     Low birth weight ([@B34])                                   ↑                            
                     Smoking ([@B67], [@B70])             ↓                      ↑                      ↑     ↓
                     Coffee ([@B68])                                             ↑                            ↑
                     Sweetened beverages ([@B46])                                ↑                      ↑ ±   
  *Reduced risk*     Alcohol ([@B66], [@B69])             ↓                      ↓                      ↓     
                     Fatty fish ([@B45])                                         ↓                            
                     Physical activity ([@B15]; [@B30])   ↓                      ↓                      ↓     
  *No association*   Serious life events ([@B72])                                →                            
                     Smokeless tobacco use ([@B71])                              →                            
                                                                                                              

↑, increased risk; ↓, reduced risk; →, no association.

∗

,↑, Positive association or higher mean/median level in exposed than unexposed; ↓, Negative association or lower mean/median in exposed than unexposed. ± HOMA-IR 3.7 vs. 2.5,

P

= 0.0561 in high (\>2 servings per day) compared to low consumers

.

![Association between BMI and HOMA-IR in LADA and type 2 diabetes. The curved line represents results of a regression and the shaded surface represents 95% confidence intervals. Data from the ESTRID-study (data set described in [@B31]).](fphys-10-00320-g003){#F3}

![Association between BMI and GADA levels in LADA. The curved line represents results of a regression and the shaded surface represents 95% confidence intervals. Data from the ESTRID-study (data set described in [@B31]).](fphys-10-00320-g004){#F4}

#### Environmental factors in LADA associated with autoimmunity and type 1 diabetes

What triggers autoimmunity besides genetic factors is not clear; Psychological stress has been linked to type 1 diabetes in children ([@B74]) but no such association was seen with LADA ([@B72]). In line with some findings regarding type 1 diabetes in children ([@B84]; [@B59]; [@B57]), fatty fish is associated with a reduced risk of LADA but unrelated to type 2 diabetes in the ESTRID Study ([@B45]). A beneficial effect could hypothetically be attributed to omega 3-fatty acids which are abundant in fatty fish and possessing anti-inflammatory and immunomodulatory properties ([@B12]). Moreover, coffee consumption is positively associated with the risk of LADA in carriers of HLA high risk genotypes, as well as with GADA levels ([@B68]), which is in contrast with the reduced risk of type 2 diabetes consistently shown in high consumers of coffee ([@B16]). This may be a spurious finding but interestingly, an earlier study on type 1 diabetes with onset in adolescence showed a similar association ([@B94]). A mechanism remains to be established but as outlined in a recent review, several components of coffee may have immunomodulatory effects ([@B78]). Since the HUNT Study has limited information on dietary factors, these findings are solely based on data from the ESTRID Study and should clearly be interpreted with caution.

#### Inconsistencies

Results were consistent across the HUNT and ESTRID-studies for BMI, physical activity and alcohol intake ([Table 2](#T2){ref-type="table"}) but not for smoking which was associated with a significantly increased risk in the Swedish data ([@B70]) and a reduced risk in the Norwegian data ([@B67]). Previous studies have shown that whereas smoking is associated with an increased risk of type 2 diabetes, primarily attributed to negative effects of nicotine on insulin sensitivity, several studies have linked parental smoking to a reduced risk of type 1 diabetes in the offspring ([@B20]; [@B50]), including a recent study on maternal smoking during pregnancy based on data from three different cohorts ([@B50]). The authors speculate that a beneficial influence may be due to immune suppressive effects of nicotine ([@B50]). Interestingly, in LADA patients, smoking is positively associated with insulin resistance and negatively associated with GADA levels ([@B67], [@B70]). This indicates that smoking may confer both positive and negative effects and population characteristics including degree of underlying autoimmunity may determine whether the net effect is beneficial or detrimental. The effects may also cancel out each other which may explain why we did not find an association between use of Swedish oral moist snuff and LADA ([@B71]). Interaction with genetic factors may account for some of this heterogeneity; notably, strong interaction between smoking and HLA genotypes has been demonstrated in relation to rheumatoid arthritis ([@B39]) but this remains to be explore in relation to LADA.

Discussion
==========

Despite the autoimmune nature of LADA and clear genetic overlap with type 1 diabetes, studies on lifestyle and LADA risk indicate that factors such as overweight and physical inactivity that are associated with insulin resistance and type 2 diabetes may also promote LADA. This indicates that insulin resistance may play a key role in the pathogeneses of LADA together with autoimmune destruction of the insulin producing beta-cells. Based on current knowledge, one can create a model over LADA development where the first step in disease development is genetically triggered autoimmunity that slowly destroys the beta-cells and reduces insulin release. At a second stage, exposure to unhealthy lifestyle factors leads to insulin resistance and increased demand on the beta-cells for a compensatory rise in insulin production. Eventually the beta-cells will fail to meet the increasing insulin need, resulting in hyperglycemia and LADA becomes manifest ([Figure 5](#F5){ref-type="fig"}).

![Etiology of LADA, model based on current knowledge.](fphys-10-00320-g005){#F5}

![Association between HOMA-IR and GADA levels in LADA. The curved line represents results of a regression and the shaded surface represents 95% confidence intervals. Data from the ESTRID-study (data set described in [@B31]).](fphys-10-00320-g006){#F6}

This fits with the accelerator hypothesis ([@B96]), which proposes that insulin resistance may be involved in the promotion of all forms of diabetes by stressing the beta-cells, possibly accelerating the autoimmune process as well as beta-cell apoptosis. In line with this reasoning, excessive weight has also been linked to the risk of type 1 diabetes in children ([@B93]). The relative importance of insulin resistance for disease progression will most likely depend on the degree of underlying autoimmunity; if autoimmunity is severe enough, the influence of factors promoting insulin resistance is most likely minor. Consistent with this hypothesis, data from the ESTRID Study ([@B31]) show a negative association between GADA and HOMA-IR in LADA patients at time of diagnosis ([Figure 6](#F6){ref-type="fig"}). This also fits with reasoning by Naik et al. who proposed that insulin resistance will determine at what point in the autoimmune process LADA will become manifest ([@B55]).

Opportunities for Prevention
----------------------------

Intervention studies show that it is possible to prevent type 2 diabetes by lifestyle modification ([@B90]; [@B40]). In the Finnish Diabetes Prevention Study and the United States Diabetes Prevention Program, a 58% risk reduction among individuals with pre-diabetes was achieved by diet modification (e.g., increase in fiber intake and reduction of fat intake) and increased physical activity, with weight loss as the key factor behind the protective effect. A partly similar etiology of LADA suggests that it may also be possible to prevent or postpone LADA through the same lifestyle modifications. The fact that GADA has been detected in LADA patients several years prior to diagnosis suggests that LADA, similar to type 2 diabetes, has a long pre-diabetic phase ([@B47]; [@B81]) during which it may be possible to intervene. The preventive potential can be expected to be smaller for LADA than for type 2 diabetes where insulin resistance is the main driver of disease development. In line with this, the population attributable fraction of cases attributed to overweight/obesity in the ESTRID Study was estimated at 31% for LADA and 82% for type 2 diabetes ([@B31]). In order to investigate whether lifestyle intervention may reduce LADA risk, intervention studies are needed and such studies could target people with high risk, e.g., those with high genetic risk or antibody positivity similar to what has been done in type 1 diabetes ([@B79]). Unfortunately, it has proved to be very difficult to prevent type 1 diabetes in children ([@B79]). However, the trials conducted to date have primarily targeted factors with hypothesized effect on development and progression of autoimmunity and not insulin resistance which could prove to be fruitful in the prevention of LADA. Consistent with findings in children, adult carriers of autoantibodies are at increased risk of developing diabetes ([@B47]), and screening of non-diabetic individuals indicate that 0.7--4.7% of the general population display such autoantibody positivity ([@B76]; [@B47]; [@B75]; [@B82]). Such individuals may be suitable targets for intervention studies, under the assumption that whether a person acquires insulin resistance determines if and when the autoimmune reaction will result in hyperglycemia. Furthermore, preliminary findings based on the ESTRID and HUNT studies ([@B33]) indicate that the combination of HLA genotypes, in particular DR4/4, and overweight dramatically increases the risk of LADA. Carriers of these genotypes may also be considered for intervention studies focusing on weight reduction.

Much Remains to Be Explored
---------------------------

At this point it has to be stressed that current knowledge of the role of lifestyle factors in the etiology of LADA is still very limited. There are few studies and they are all based on data from two Scandinavian studies. The HUNT and ESTRID studies have limitations; HUNT has the advantage of being a prospective cohort study, at the same time the number of patients is small. ESTRID on the other hand, is based on more than twice as many cases but uses a case-control design which is more efficient for rare conditions, but implies that lifestyle information is collected retrospectively and this may introduce recall bias. Strengths of the studies include the detailed information on lifestyle and genetic information, careful characterization of cases and population-based design. Moreover, the consistency of findings across the two cohorts provides support for the validity of the data at hand. Interestingly, data from the Swedish ESTRID-study suggests a protective effect of fatty fish ([@B45]) and a harmful effect of coffee consumption ([@B68]) on the risk of LADA, that is not seen for type 2 diabetes. Moreover, findings regarding smoking seemed to go in opposite directions in the Swedish ([@B70]) and Norwegian data ([@B67]). Replications of these findings in other populations are clearly warranted and there are many potential risk factors that remain to be investigated. This is especially true for dietary factors. Moreover, gene^∗^environment interaction in LADA is an important but currently unexplored field. Since lifestyle factors are likely to act on genetic susceptibility in the promotion of LADA, this is important to address if we want to understand how LADA develops.

What About Prognosis?
---------------------

So what does the specific pathogenesis of LADA entail in terms of prognosis and disease management? Data from a small number of studies indicate that LADA patients have worse glycemic control than patients with type 2 diabetes ([@B60]; [@B27]) which may be due to the limited endogenous insulin production. Lack of established treatment guidelines may also play a role; as outlined in a recent review there is a shortage of randomized clinical trials in LADA and the optimal treatment regimen is still unknown ([@B26]). Moreover, in the absence of autoantibody testing, LADA patients are likely to be diagnosed as having type 2 diabetes and treated according to such recommendations, which may not be optimal. The combination of poor glycemic control and insulin resistance, together with other features of the metabolic syndrome may put individuals with LADA at high risk of complications. As summarize in a recent review ([@B11]), data from the few studies conducted to date indicate that the risk of both micro- and macro vascular complications is at least as high in LADA as in type 2 diabetes patients, in spite of their generally healthier metabolic profile. The long term consequences of LADA and the role of different prognostic factors such as treatment and lifestyle are important to elucidate in order to improve secondary prevention. As pointed out by [@B11], future studies need to take into account the heterogeneous nature of LADA; the degree of underlying autoimmunity and subsequent beta-cells loss will most likely affect response to treatment as well as prognosis.

Conclusion
==========

Taken together, studies conducted to date indicate that LADA, similar to type 2 diabetes, results from an imbalance between insulin sensitivity and insulin secretion. However, the relative contribution of insulin deficiency to disease progression is greater in LADA and of different origin, namely due to the same autoimmune pathogenesis underlying type 1 diabetes. The findings of an association between unhealthy lifestyle factors and LADA opens up the possibility that LADA to some extent may be prevented through the same lifestyle modifications as type 2 diabetes, including healthy diet, increased physical activity and subsequent weight loss. Intervention studies to test this hypothesis are needed and such studies may proposedly target GADA positive individuals without manifest diabetes or individuals with high genetic risk.
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